BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• Lexaria Receives Conditional Ethics Board Approval for Pilot Human Study Using DehydraTECH Technology in Delivering Antiviral Drugs

  Company Raises Commitment to Antiviral Research with Launch of Rodent Antiviral Drug Delivery Study with Potential COVID-19 Applications

  September 29, 2020

   · 

  7 min read
• Policy

  Aerie Pharmaceuticals Announces Acceptance of Its Investigational New Drug Application for AR-15512 (TRPM8 Agonist) Eye Drop for Dry Eye Disease

  Aerie Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has reviewed the Investigational New Drug Application for AR-15512 eye drop for dry eye and it is now in effect, allowing Aerie to initiate clinical studies in the treatment of dry eye.

  September 29, 2020

   · 

  7 min read
• BioCapital

  Orthopaedic and Spine Center Recognized for Excellence In Healthcare Service

  The practice and its physicians recognized with eight awards by the community and area physicians

  September 29, 2020

   · 

  1 min read
• Deals

  Axsome Therapeutics Announces $225 Million Term Loan Facility with Hercules Capital

  Axsome Therapeutics, Inc., a biopharmaceutical company developing novel therapies for the management of central nervous system disorders, has secured a $225 million term loan facility with Hercules Capital, Inc.

  September 29, 2020

   · 

  6 min read
• Drug Development

  Sorrento Releases Preclinical Data for STI-1499 (COVI-Guard™) and STI-2020 (COVI-AMG™), Potent Neutralizing Antibodies Against SARS-CoV-2

  In preclinical studies, both STI-1499 and STI-2020 demonstrated potent neutralizing activity against SARS-CoV-2 virus isolates, including the emerging Spike D614G variant virus.

  September 29, 2020

   · 

  7 min read
• Glaucoma Therapeutics Market: Specialty Clinics Segment to Expand at Rapid Pace

  Glaucoma is a disease that damages the optic nerve and its progression could result in vision loss and blindness.

  September 29, 2020

   · 

  6 min read
• Osteoarthritis Drugs Market: Osteoarthritis Drugs Market: Growing Elderly Population a Major Driver of the Market

  The global osteoarthritis drugs market is expected to reach a market value of about US$ 11,226.1 Mn by the end of 2026, expanding at a high single digit CAGR during the forecast period.

  September 29, 2020

   · 

  5 min read
• Spine Surgery Robots Market: Companies Expanding Their Presence through Mergers & Acquisitions and CE Marking

  A rapid rise in the use of spine surgical robots is attributed to a blend of technological improvements.

  September 29, 2020

   · 

  5 min read
• Polyphor Announces Closing of Fosun Pharma Licensing Agreement for balixafortide in China and Receipt of $15 Million Upfront Payment

  Polyphor AG announced the closing of the previously announced exclusive licensing agreement with Fosun Pharma for balixafortide in China.

  September 29, 2020

   · 

  2 min read
• Pharnext to Host Research and Development Day on October 13, 2020

  Pharnext SA announced that it will host a research and development day focused on the company’s development efforts related to its lead asset, PXT3003, in Charcot-Marie-Tooth disease type 1A on Tuesday, October 13, 2020, from 8:00 - 10:30 a.m. ET / 2:00 - 4:30 p.m. CET.

  September 29, 2020

   · 

  3 min read